PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SRTS vs. GENE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SRTS and GENE is 0.06, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

SRTS vs. GENE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%SeptemberOctoberNovemberDecember2025February
-18.00%
-14.69%
SRTS
GENE

Key characteristics

Fundamentals

Market Cap

SRTS:

$94.19M

GENE:

$3.71M

EPS

SRTS:

$0.41

GENE:

-$0.02

PEG Ratio

SRTS:

0.00

GENE:

0.00

Total Revenue (TTM)

SRTS:

$28.74M

GENE:

$7.20M

Gross Profit (TTM)

SRTS:

$17.33M

GENE:

$4.19M

EBITDA (TTM)

SRTS:

$6.48M

GENE:

-$8.06M

Returns By Period


SRTS

YTD

-19.65%

1M

-18.71%

6M

-17.99%

1Y

19.06%

5Y*

5.14%

10Y*

N/A

GENE

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SRTS vs. GENE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRTS
The Risk-Adjusted Performance Rank of SRTS is 5757
Overall Rank
The Sharpe Ratio Rank of SRTS is 5454
Sharpe Ratio Rank
The Sortino Ratio Rank of SRTS is 5858
Sortino Ratio Rank
The Omega Ratio Rank of SRTS is 5858
Omega Ratio Rank
The Calmar Ratio Rank of SRTS is 5757
Calmar Ratio Rank
The Martin Ratio Rank of SRTS is 5858
Martin Ratio Rank

GENE
The Risk-Adjusted Performance Rank of GENE is 77
Overall Rank
The Sharpe Ratio Rank of GENE is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of GENE is 44
Sortino Ratio Rank
The Omega Ratio Rank of GENE is 33
Omega Ratio Rank
The Calmar Ratio Rank of GENE is 88
Calmar Ratio Rank
The Martin Ratio Rank of GENE is 1414
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SRTS vs. GENE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SRTS, currently valued at 0.21, compared to the broader market-2.000.002.000.21-0.94
The chart of Sortino ratio for SRTS, currently valued at 0.94, compared to the broader market-4.00-2.000.002.004.006.000.94-1.38
The chart of Omega ratio for SRTS, currently valued at 1.13, compared to the broader market0.501.001.502.001.130.77
The chart of Calmar ratio for SRTS, currently valued at 0.23, compared to the broader market0.002.004.006.000.23-0.63
The chart of Martin ratio for SRTS, currently valued at 1.01, compared to the broader market-10.000.0010.0020.0030.001.01-0.98
SRTS
GENE


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
0.21
-0.94
SRTS
GENE

Dividends

SRTS vs. GENE - Dividend Comparison

Neither SRTS nor GENE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SRTS vs. GENE - Drawdown Comparison


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%SeptemberOctoberNovemberDecember2025February
-62.86%
-98.25%
SRTS
GENE

Volatility

SRTS vs. GENE - Volatility Comparison

Sensus Healthcare, Inc. (SRTS) has a higher volatility of 46.55% compared to Genetic Technologies Limited (GENE) at 0.00%. This indicates that SRTS's price experiences larger fluctuations and is considered to be riskier than GENE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February
46.55%
0
SRTS
GENE

Financials

SRTS vs. GENE - Financials Comparison

This section allows you to compare key financial metrics between Sensus Healthcare, Inc. and Genetic Technologies Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab